AC
RNTX

Armistice Capital’s Rein Therapeutics RNTX Stock Holding History

Armistice Capital’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-60,000
Closed -$864K – 84
2019
Q2 		$864K Sell
60,000
-101,692
-63% -$2.67M 0.05% 60
2019
Q1 		$6.31M Buy
+161,692
New +$5.04M 0.35% 52

Other funds holding RNTX

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Armistice Capital's RNTX Position: Q3 2019 in Review

Armistice Capital sold out of Rein Therapeutics (RNTX) in Q3 2019, closing a stake of 60,000 shares — an estimated $864K sold.

Armistice Capital first reported a position in RNTX in Q1 2019 and held it in 2 quarters. The position peaked at $6.31M in Q1 2019. 22 funds tracked by Wall St. Rank hold RNTX as of Q3 2019.

  • Armistice Capital reported no remaining Rein Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Armistice Capital sold 60,000 Rein Therapeutics shares in Q3 2019, an estimated $864K.
  • Armistice Capital first reported a position in Rein Therapeutics in Q1 2019 and held it in 2 quarters.
  • Armistice Capital's Rein Therapeutics position peaked at $6.31M in Q1 2019.
  • 22 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2019.

Based on Armistice Capital's 13F filing for Q3 2019, filed 14 Nov 2019.